All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @tiana.prime on TikTok · 44s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @tiana.prime's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00Okay guys this is tonight's stack. We've got GHK-Cu, we've got MT2 and we've got
  2. 0:05ready to retire. I've already cleaned the top of each vial and now we're going
  3. 0:12to draw our dosage. 2.5 MG of GHK-Cu just because I've diluted it with a lot of
  4. 0:21backwater. 10 units of MT2 and tonight's dose 4 redder is just 10 units or 1 MG
  5. 0:32just half of my dose. So I take redder twice a week and I take half of a dose
  6. 0:38at each time and that's my stack.

TikTok peptide claims without the video? We can't check

T

TikTok creator

10.6K viewsWatch on TikTok

Quick answer

The video documents self-administration of three unapproved peptides: GHK-Cu (copper peptide with topical wound-healing evidence), MT-II (a melanocortin agonist with cardiovascular and dermatological risk signals), and likely BPC-157 at a dose of 1 mg twice weekly. None of these compounds are FDA-approved for any indication, and MT-II in particular carries documented risks including blood pressure changes and melanocytic lesion development that are absent from this content. No prescriber, clinical indication, or monitoring protocol is mentioned.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

Peptide social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 9 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For TikTok peptide claims without the video? We can't check, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

TikTok peptide claims without the video? We can't check is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "TikTok peptide claims without the video? We can't check" from T. We read the clip as a Peptide social video fact-checks claim about Peptide social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The video documents self-administration of three unapproved peptides: GHK-Cu (copper peptide with topical wound-healing evidence), MT-II (a melanocortin agonist with cardiovascular and dermatological risk signals), and likely BPC-157 at a dose of 1 mg twice weekly.

The reason this review is not generic is the source wording and the canonical claim label "peptides tiktok 7623338235300711700." In this clip, the useful excerpt is: "Okay guys this is tonight's stack." That wording changes the review because it points to Peptide social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Multifunctionality and Possible Medical Application of the BPC 157 Peptide (2025), Gastric pentadecapeptide BPC 157 and its role in accelerating musculoskeletal soft tissue healing (2019), and Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review (2025), plus the creator's own wording. Peptide social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Saying '10 units' of a peptide solution without stating concentration tells viewers nothing about actual dose.
People who land here are usually trying to understand whether the Peptide social video fact-checks claim is evidence-backed, safe, and relevant to their own situation.
The strongest next step is to compare the claim with FormBlends' Peptide social video fact-checks guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

The video documents self-administration of three unapproved peptides: GHK-Cu (copper peptide with topical wound-healing evidence), MT-II (a melanocortin agonist with cardiovascular and dermatological risk signals), and likely BPC-157 at a dose of 1 mg twice weekly.

FormBlends verdict

Peptide social video fact-checks evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • The video documents self-administration of three unapproved peptides: GHK-Cu (copper peptide with topical wound-healing evidence), MT-II (a melanocortin agonist with cardiovascular and dermatological risk signals), and likely BPC-157 at a dose of 1 mg twice weekly. None of these compounds are FDA-approved for any indication, and MT-II in particular carries documented risks including blood pressure changes and melanocytic lesion development that are absent from this content. No prescriber, clinical indication, or monitoring protocol is mentioned.
  • MT-II (Melanotan II) is not FDA-approved for any use and has been linked to melanocytic lesion changes in at least one BMJ case report (Coelho et al., 2009), a risk absent from this video.
  • Saying '10 units' of a peptide solution without stating concentration tells viewers nothing about actual dose. This is a basic safety gap.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • MT-II (Melanotan II) is not FDA-approved for any use and has been linked to melanocytic lesion changes in at least one BMJ case report (Coelho et al., 2009), a risk absent from this video.
  • Saying '10 units' of a peptide solution without stating concentration tells viewers nothing about actual dose. This is a basic safety gap.
  • GHK-Cu's published evidence base is almost entirely topical or in vitro. Systemic injectable use in humans lacks controlled clinical trial data.
  • BPC-157 has zero completed randomized controlled trials in humans as of 2024. Animal data is promising but cannot be directly extrapolated to human dosing or safety.
  • All three peptides shown fall outside FDA-approved drug status. Legal human use in the U.S. requires a valid prescription from a licensed provider through a registered compounding pharmacy.
  • Correct sterile technique, which this creator does demonstrate, reduces infection risk but does not address pharmacological risks of the compounds themselves.
  • Stacking multiple unapproved compounds with overlapping receptor activity (MT-II affects melanocortin receptors broadly, including cardiovascular pathways) without clinical monitoring is not a practice any regulated provider would endorse.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @tiana.prime actually say?

@tiana.prime walked viewers through a self-administered subcutaneous injection stack: "2.5 MG of GHK CU," "10 units of MT2," and "10 units or 1 MG" of what she calls "redder" (almost certainly BPC-157, based on her dosing pattern and the twice-weekly schedule she describes). She notes she diluted her GHK-Cu with a significant volume of bacteriostatic water. She takes BPC-157 "twice a week" at "half of a dose at each time." There's no mention of a prescribing physician, a clinical indication, or lab monitoring. The video is essentially a how-I-inject tutorial for three unapproved, unregulated peptides, served to 10,000+ viewers who may have no medical supervision at all.

Does the science back this up?

The honest answer is: partially, for some of these compounds, in animal models and early human data. Not across the board, and not at the doses she's describing without clinical oversight.

GHK-Cu (copper peptide) has the strongest legitimate research base of the three here. Studies including Pickart and Margolina (2018, Cosmetics) document its role in wound healing, collagen synthesis, and anti-inflammatory signaling. Most of that evidence, however, is topical or in vitro. Systemic injectable use in humans is not well-studied.

MT-II (Melanotan II) is a non-selective melanocortin receptor agonist. It does cause skin tanning and has documented effects on sexual arousal, which is likely why it's used recreationally. But it carries real cardiovascular and dermatological risks. Wessells et al. (2000, Urology) showed modest effects on erectile function, but side effects including nausea, facial flushing, and spontaneous erections were common. It is not FDA-approved for any indication.

BPC-157 (Body Protection Compound 157) has intriguing animal data on gut healing and tendon repair (Sikiric et al., 2018, Current Pharmaceutical Design), but zero completed randomized controlled trials in humans. Calling it proven at this stage is premature.

What did they get wrong (or right)?

Credit where it's due: diluting peptides with bacteriostatic water is the correct reconstitution method, and cleaning vial tops before drawing is basic sterile technique. She's doing the mechanical steps right.

What she got wrong, or at least left dangerously incomplete: there is no context for why she's taking these compounds, no mention of medical supervision, and no disclosure of the real risk profile of MT-II. Melanotan II has been linked to melanocytic nevi changes (moles that can appear or darken), blood pressure spikes, and nausea severe enough to be disabling for some users. A 2009 case report in the BMJ (Coelho et al.) documented a changing melanocytic lesion in a young man who used MT-II. Showing injection technique without this context is irresponsible, regardless of how clean her needle drawing is.

The dose she describes for BPC-157 (1 mg, twice weekly) is well above what most peptide-prescribing clinicians use. This is not a recommendation either way, but the absence of any discussion of dosing rationale is a gap that matters.

What should you actually know?

None of these three peptides are FDA-approved drugs. They are sold as research chemicals in the U.S. and are not legal to market for human use outside of a licensed compounding pharmacy operating under a valid prescription. That regulatory reality matters because it means no quality control standard applies to what you're actually injecting.

MT-II in particular carries a risk profile that casual TikTok content almost never addresses. Beyond cosmetic tanning, it acts on brain receptors in ways that affect blood pressure, appetite, and sexual function simultaneously. The "10 units" framing in the video tells viewers nothing about the concentration of her solution, which determines actual dose entirely.

GHK-Cu at 2.5 mg injectable is unusual. Most studied applications are topical. If someone is prescribing injectable GHK-Cu systemically, that's an off-label use with limited safety data in humans. That doesn't make it automatically dangerous, but it deserves acknowledgment.

If you're curious about peptide therapy, that conversation belongs with a licensed clinician who can evaluate your actual health status, not a TikTok comment section.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

T · TikTok creator

10.6K views on this video

TikTok peptide claims without the video? We can't check

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about mt-ii (melanotan ii)?

MT-II (Melanotan II) is not FDA-approved for any use and has been linked to melanocytic lesion changes in at least one BMJ case report (Coelho et al., 2009), a risk absent from this video.

What does the video say about saying '10 units' of a peptide solution without stating concentration?

Saying '10 units' of a peptide solution without stating concentration tells viewers nothing about actual dose. This is a basic safety gap.

What does the video say about ghk-cu's published evidence base?

GHK-Cu's published evidence base is almost entirely topical or in vitro. Systemic injectable use in humans lacks controlled clinical trial data.

What does the video say about bpc-157 has zero completed randomized controlled trials in humans as?

BPC-157 has zero completed randomized controlled trials in humans as of 2024. Animal data is promising but cannot be directly extrapolated to human dosing or safety.

What does the video say about all three peptides shown fall outside fda-approved drug status. legal?

All three peptides shown fall outside FDA-approved drug status. Legal human use in the U.S. requires a valid prescription from a licensed provider through a registered compounding pharmacy.

What does the video say about correct sterile technique,?

Correct sterile technique, which this creator does demonstrate, reduces infection risk but does not address pharmacological risks of the compounds themselves.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by T, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.